Article ID Journal Published Year Pages File Type
2007733 Peptides 2007 12 Pages PDF
Abstract

We have utilized a rat model of peripheral artery disease (PAD) to examine whether the known angiogenic activity of the Y2 receptor would translate into a meaningful increase in collateral blood flow. The maximal increase in collateral blood flow capacity of ∼60% (p < 0.001) was obtained with a 10 μg/kg day (IA infusion, 14 days) of either PYY or PYY3–36 and did not differ from that obtained with a maximally angiogenic dose of VEGF165. Pharmacodynamic modeling based upon single dose pharmacokinetic plasma profiles of both agonists suggests that Emax is reached when the Y2 receptor is occupied by ≥50%. Furthermore, for PYY3–36, occupancy of the Y2 receptor is sufficient to promote a significant benefit in collateral blood flow.

Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Biochemistry
Authors
, , , , , , , , , , , ,